Day: March 29, 2021

HIGHCO : Transactions sur Actions propres du 22/03/21 au 26/03/21

Written by Customer Service on March 29, 2021. Posted in Public Companies.

Déclaration des transactions sur actions propresRéalisées du 22 au 26 mars 2021 Paris, le 29 mars 2021 Présentation agrégée par jour et par marchéNom de l’émetteur Code identifiant émetteur Jour de la transaction Code identifiant de l’instrument financier Volume total journalier(en nombre d’actions) Prix pondéré moyen journalier d’acquisition des actions MarchéHIGH CO 969500FYLNRXCJ348W66 24/03/2021 FR 0000054231 1 000 5,38 € XPARHIGH CO 969500FYLNRXCJ348W66 25/03/2021 FR 0000054231 1 000 5,50 € XPARHIGH CO 969500FYLNRXCJ348W66 26/03/2021 FR 0000054231 1 000 5,55 € XPARPrésentation détaillée transaction par transaction Code identifiant PSI JourHeure de la transaction Code identifiant de l’instrument financier Prix unitaire (unité) Devise Quantité achetée Code identifiant marché Numéro de référence de la transaction Objectif...

HIGHCO : Transactions sur Actions propres du 22/03/21 au 26/03/21

Written by Customer Service on March 29, 2021. Posted in Public Companies.

Tegningens forløb i Sydinvest Bæredygtige Aktier A DKK

Written by Customer Service on March 29, 2021. Posted in Public Companies.

(Selskabsmeddelelse 14/2021) Tegningen af andele i Sydinvest Bæredygtige Aktier A DKK blev afsluttet den 26. marts 2021. Der blev tegnet følgende nye beviser i tegningsperioden:Navn ISIN Antal investorer Antal beviser Tegnet beløbSydinvest Bæredygtige Aktier A DKK DK0061533643 501 1.642.665 165 mio. kr.Beviserne optages til handel på Nasdaq Copenhagen fra og med den 6. april 2021. Beviserne betales den 31. marts 2021 og afregnes kutymemæssigt samtidigt med registreringen i Værdipapircentralen. Yderligere informationer fås på foreningens hjemmeside www.sydinvest.dk eller ved henvendelse til Syd Fund Management A/S. Venlig hilsen Syd Fund Management A/S Tlf. 74 37 33 00

Polarcus: Joint Provisional Liquidators’ report to Grand Court of the Cayman Islands

Written by Customer Service on March 29, 2021. Posted in Public Companies.

Polarcus Limited (in provisional liquidation) (“Polarcus” or the “Company”) (OSE: PLCS) refers to the announcement issued on 11 March 2021 (Polarcus: Share Suspension) that the Joint Provisional Liquidators (“JPLs”) to the Company were required to submit a report to the Grand Court of the Cayman Islands (“Court”) by no later than 31 March 2021. The JPLs’ first report has now been filed at the Court. The report summarises the work undertaken since the JPLs’ appointment on 8 February 2021, provides an estimated financial position of the Company and its subsidiaries, and provides comments on further work to be undertaken by the Company and the JPLs in the near term. The JPLs’ priority is on completing its negotiations with certain secured creditors, and in so doing seeking to maximise returns for the Company’s creditors as a whole....

Casino Group announces the launch of a new unsecured bond

Written by Customer Service on March 29, 2021. Posted in Public Companies.

THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE OR FORM PART OF ANY OFFER OR INVITATION TO SELL OR ISSUE, OR ANY SOLICITATION OF AN OFFER TO PURCHASE OR SUBSCRIBE FOR, ANY SECURITIES OF CASINO, GUICHARD-PERRACHON S.A. NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH IT WOULD BE UNLAWFUL TO DO SO. PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS. Casino Group is launching a new senior unsecured bond maturing in April 2027 Paris, 29 March 2021, As part of the debt refinancing transaction announced on 22 March 2021, Casino Group is today launching a new senior unsecured bond maturing in April 2027...

Le groupe Casino annonce le lancement d’une nouvelle obligation non sécurisée

Written by Customer Service on March 29, 2021. Posted in Public Companies.

CE COMMUNIQUÉ DE PRESSE EST A TITRE INFORMATIF UNIQUEMENT. Il NE CONSTITUE NI NE FAIT PARTIE D’UNE OFFRE OU D’UNE INVITATION À VENDRE OU ÉMETTRE, ET NE REPRÉSENTE PAS UNE INCITATION À ACHETER OU SOUSCRIRE DES TITRES DE CASINO, GUICHARD-PERRACHON S.A. À NE PAS DISTRIBUER À DES SERVICES D’AGENCE DE PRESSE AMERICAINS NI À DIFFUSER AUX ÉTATS-UNIS, EN AUSTRALIE, AU CANADA OU AU JAPON OU À TOUT AUTRE PAYS OÙ UNE TELLE DIFFUSION SERAIT INTERDITE PAR LA LOI. VEUILLEZ LIRE ATTENTIVEMENT LES AVERTISSEMENTS IMPORTANTS À LA FIN DE CE COMMUNIQUÉ DE PRESSE. LE NON-RESPECT DE CES RESTRICTIONS PEUT CONSTITUER UNE VIOLATION DU DROIT DES VALEURS MOBILIÈRES DES ÉTATS-UNIS. Le Groupe Casino émet unenouvelle obligation non sécurisée de maturité avril 2027 Paris, le 29 mars 2021 Dans le cadre de l’opération de refinancement de sa dette annoncée le 22 mars...

Guerbet: Additional information related to 2021 financial outlook

Written by Customer Service on March 29, 2021. Posted in Public Companies.

Additional information related to 2021 financial outlook Villepinte, March 29, 2021 – Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is detailing information related to 2021 outlook disclosed in the March 24th, 2021 press release entitled “2020 Annual Results”. In terms of profitability, the company is targeting the following EBITDA trends:Short term, a growing EBITDA in 2021, with a minimum rate EBITDA/SALES equal to 2020 (14.1%) Medium term, an improving EBITDA/SALES rate, ensuring strong, lasting growth for the GroupA detailed presentation of 2020 Annual Results is available under Investor Relation headings, on Guerbet’s site https://www.guerbet.com/investors/. Upcoming events: Reporting of Q1 2021 revenue April 22, 2021, after trading About Guerbet Guerbet is a leader in medical...

GUERBET: Précisions sur les perspectives financières 2021

Written by Customer Service on March 29, 2021. Posted in Public Companies.

Précisions sur les perspectives financières 2021 Villepinte, le 29 mars 2021 – Guerbet (FR0000032526), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, souhaite aujourd’hui préciser les informations relatives à ses perspectives de développement 2021 évoquées dans le précédent communiqué du 24 mars 2021 intitulé « Résultats annuels 2020 ». En termes de rentabilité opérationnelle, le Groupe ambitionne une évolution de l’EBITDA (1)comme suit :A court terme, un EBITDA 2021 en croissance, avec un taux de marge EBITDA/chiffre d’affaires au moins égal au taux de l’exercice 2020 (14,1%) A moyen terme, une ambition d’améliorer le taux d’EBITDA pour assurer au Groupe une croissance forte et durableLa présentation détaillée des résultats annuels 2020 est disponible sur la rubrique investisseurs du site de...

Resultat af aktietilbagekøb

Written by Customer Service on March 29, 2021. Posted in Public Companies.

I forlængelse af selskabsmeddelelse 3/2021 omkring aktietilbagekøb skal selskabet hermed meddele at man har købt 13.064 aktier til 1,90. Bestyrelsen har på den baggrund besluttet ikke at forlænge programmet som herved lukkes ned pr. dd. SIG ejer pr. dags dato 5.532.255 aktier, svarende til 10,33% af aktiekapitalen. Det samlede antal aktier i virksomheden er i alt 53.566.497 aktier, inklusive egne aktier. Kontakt:Evt. spørgsmål til denne meddelelse kan rettes til CEO Michael Hove på 28126609 eller mail mh@sca-inv-group.dk Venlig hilsen Bestyrelsen Vedhæftet filSelskabsmeddelelse 7_21_Resultat af aktietilbagekøb

Results for the year ended 31 December 2020

Written by Customer Service on March 29, 2021. Posted in Earnings Releases And Operating Results.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Acacia Pharma Group plc Results for the year ended 31 December 2020 Cambridge, UK and Indianapolis, US – 29 March 2021, 07:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces its results for the year ended 31 December 2020 and provides an update on progress with the commercialization of BARHEMSYS® and BYFAVO™ in the United States. A presentation by Acacia Pharma’s senior management team will be webcast live today at 14.30...

Day: March 29, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals